Improving the Quality Use of Medicines in Australia
Realising the potential of Pharmacogenomics
The prescribing of pharmaceuticals in Australia is too often a ‘hit and miss’ affair and many patients take drugs that are either ineffective or have bad side effects. A Study released in Canberra on 4 December 2008 suggests that Australia could avoid these problems and realise a net economic benefit of more than $12 billion by the wider adoption of pharmacogenomics (PGx).
PGx is the science of prescribing the safest and most effective medicine based on an individual’s biomarkers.
The Study was prepared for the Australian Centre for Health Research (ACHR) by Deloitte Economics and makes a persuasive case for PGx. It lists potentially huge savings by avoiding adverse drug events, avoidance of ‘trial and error in current prescribing methods and improved quality of care and patient compliance.
Page Last Updated